IDH1 and glioblastoma: These results revealed that three hub genes with higher expression levels (VEGFA, CXCL8, and IDH1) were associated with a significantly shorter overall survival time among patients with GBM (log-rank p ≤ 0.05 and p(HR or hazard ratio) ≤ 0.05) (Figure 6A,B), suggesting that these hub genes are associated with the pathophysiology of bevacizumab-resistant GBM.